


Please amend the application filed on even date herewith prior to proceeding with its examination.

### IN THE CLAIMS

1. (Original) Compounds of the general formula (I) (I)



in which:

A is chosen among carbocyclic aromatic groups, heterocyclic aromatic groups, and arylC<sub>1-4</sub>alkyl;

R<sub>1</sub> is chosen among:

- hydrogen,
- arylC<sub>1-7</sub>alkyl, optionally substituted on the aryl moiety with one or more groups chosen among hydroxy, C<sub>1-4</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;
- heterocyclylC<sub>1-7</sub>alkyl, optionally substituted on the heterocyclyl moiety with one or more groups chosen among C<sub>1-4</sub>alkyl and hydroxy;
- C<sub>1-7</sub> alkyl, optionally interrupted by an oxygen or sulphur atom or optionally substituted at any position by one or more groups chosen among hydroxy, thio, amino, carboxyl, aminocarbonyl, guanidiny.

R<sub>2</sub> is chosen among hydrogen, C<sub>1-4</sub>alkyl, arylC<sub>1-4</sub>alkyl and phenyl;

or else R<sub>1</sub> and R<sub>2</sub>, taken together, form a saturated carbocyclic ring containing from 3 to 8 carbon atoms;

R<sub>3</sub> is chosen among hydrogen, C<sub>1-4</sub>alkyl, arylC<sub>1-4</sub>alkyl, CONH<sub>2</sub> and COOR<sub>5</sub> in which R<sub>5</sub> is chosen between hydrogen and C<sub>1-4</sub>alkyl;

**R<sub>4</sub>** is chosen among hydrogen, C<sub>1-4</sub>alkyl, aryl, arylC<sub>1-4</sub>alkyl and heterocyclyl;

**n** is 2, 3 or 4;

in the form of a racemic mixture or in the form of enantiomers, and pharmaceutically acceptable salts or solvates thereof.

2. (Original) The compounds according to Claim 1, in which: A is phenyl, thienyl, pyridyl, pyrimidinyl group, optionally substituted, benzyl or 4-methylbenzyl; R<sub>1</sub> is hydrogen, C<sub>1-4</sub>alkyl, benzyl, -CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>CONH<sub>2</sub>, -CH<sub>2</sub>COOH, indol(3-yl)methyl; R<sub>2</sub> is hydrogen, C<sub>1-4</sub>alkyl or benzyl; R<sub>3</sub> and R<sub>4</sub> are hydrogen or methyl, and n is 2.

3. (Original) The compounds according to Claim 2, in which: A is phenyl optionally substituted; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are hydrogen; and n is 2.

4. (Currently Amended) The compounds according to Claim[s] 1[-3], in which A is substituted with 1 to 3 substituents chosen among Me, Et, i-Pr, OH, COOEt, COOH, CH<sub>2</sub>OH, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>Me, OMe, Cl, F, CN and CF<sub>3</sub>.

5. (Original) The compounds according to Claim 4, in which A is substituted with 1 to 3 substituents chosen among Me, Et, i-Pr, OH, CN, Cl and CF<sub>3</sub>.

6. (Currently Amended) The compounds according to Claim 1 [or 2], in which said C<sub>1-4</sub>alkyl group is chosen among Me, Et, i-Pr, i-Bu and cyclopropylmethyl.


7. (Currently Amended) The compounds according to Claim 1, chosen in the group consisting of:

- 1-Phenyl-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-*o*-tolyl-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-(2,6-Dimethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-Thiophen-2-yl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-*m*-Tolyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-*p*-Tolyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-(5-Fluoro-2-methyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-(3-Fluoro-2-methyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-(2-Trifluoromethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-(4-Chloro-2-methyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;
- 1-(3-Chloro-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;

1-(3-Methoxy-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3-Cyano-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Chloro-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3-Hydroxy-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3-Trifluoromethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Trifluoromethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Methoxy-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3,5-Dimethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3,4-Dimethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-Naphthalen-2-yl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3-Isopropyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Chloro-3-methyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 3-Benzyl-1-phenyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 3-Methyl-1-phenyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 3-Isobutyl-1-phenyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3-Fluoro-5-methyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3-Fluoro-4-methyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 7a-Methyl-1-phenyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 (S)-1-*o*-Tolyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 (R)-1-*o*-Tolyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Ethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Isopropyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Hydroxymethyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 4-(2,5-Dioxo-hexahydro-pyrrolo[1,2-a]imidazol-1-yl)-benzoic acid;  
 4-(2,5-Dioxo-hexahydro-pyrrolo[1,2-a]imidazol-1-yl)-benzoic acid ethyl ester;  
 1-(4-Methanesulfonyl-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Fluoro-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(4-Cyano-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-Pyridin-2-yl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-Pyridin-3-yl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;

1-(5-Methylpyridin-2-yl)-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(2-Cyano-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-(3-Fluoro-phenyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione;  
 1-Benzyl-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione; and  
 1-(4-methylbenzyl)-tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione.

8. (Currently Amended) A process for the preparation of the compounds of formula (I) as described in Claim 1, comprising the step of reacting [the reaction of] a compound of formula (II)



(II)

with a compound of formula (III)

A-X

(III)

in which A,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $n$  are defined as in Claim 1, and X is a halogen atom, to obtain the desired compounds of formula (I).

9. (Original) The process according to Claim 8, in which in the compound of formula (III) X is chosen between bromine and iodine.

10. (Currently Amended) The process according to Claim[s] 8[-9], for the preparation of the compounds of formula (I) wherein A is a carbocyclic aromatic group or a heterocyclic aromatic group, optionally substituted, in which the compound of formula (II) is dissolved in an appropriate solvent together with the compound of formula (III) in the presence of a base and of a catalytic amount of a copper salt, at a temperature of between 60°C and 140°C.


11. (Original) The process according to Claim 10, in which said solvent is *N*-methylpyrrolidone, said base is potassium carbonate, said copper salt is copper iodide, and the reaction is conducted at a temperature of 120°C.

12. (Currently Amended) The process according to Claim[s] 8[-9], for the preparation of the compounds of formula (I) wherein A is arylC<sub>1-4</sub>alkyl, in which the compound of formula (II) is dissolved in an appropriate solvent together with the compound of formula (III), in the presence of a suitable base at a temperature between 60°C and 140°C.

13. (Original) The process according to claim 12, in which said solvent is chosen among acetonitrile, methylene chloride, acetone, said base is chosen among triethylamine, potassium carbonate, 2-*tert*-Butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine, N,N-Diiso-propylethylamine, at a temperature of 100°C.

14. (Currently Amended) The process for the preparation of compounds of formula (I) as described in Claim 1, comprising the following stages:

i) reacting [reaction of] an aminoacid of formula (IV) or of one of its activated derivatives




(IV)

with a compound of formula (V)

A-NH<sub>2</sub>

(V)


to obtain a compound of formula (VI):



in which R<sub>1</sub>, R<sub>2</sub> and A are as defined above in Claim 1, and P is H or a suitable protective group;


ii) [reaction of] reacting the compound of formula (VI) obtained in stage i) with a compound of

formula (VII)



(VII)

to obtain a compound of formula (VIII)



(VIII)

in which A, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and n are as defined in Claim 1, P is defined as above, and R' is an alkyl group;

iii) optionally removing [possible removal of] the protective group P by means of hydrogenolysis of the compound of formula (VIII) obtained from stage ii), to obtain the corresponding compound (VIII), in which P is H; and

iv) cyclizing [cyclization] of the compound of formula (VIII), in which P is H coming from stage ii) or from stage iii), to obtain the desired compound of formula (I).

15. (Original) The process according to Claim 14, in which R' is chosen between methyl

and *tert*-butyl, and P is chosen between H, benzyl and benzyloxycarbonyl.

16. (Original) The process according to Claim 14, in which, in said stage iv), the cyclization reaction is carried out by heating the compound (VIII) in the absence of solvent at 120°C and in vacuum conditions, or else by reflux-heating the compound (VIII) in xylene for a time comprised between 4 hours and 3 days.
17. (Original) The process according to Claim 14, in which said stage ii) is conducted by reflux-heating the compounds of formula (VI) and (VII) in a protic solvent for a time comprised between 2 and 24 hours, possibly in the presence of a base.
18. (Original) The process according to Claim 14, in which the reaction described in stage i) is conducted between the acidic chloride of the compound (IV) and the compound (V) in the presence of an inorganic or organic base in a suitable aprotic solvent at a temperature of between -70°C and 50°C.
19. (Original) The process according to Claim 14, in which the reaction of stage i) is conducted by reacting together the compound (IV) and the compound (V) in the presence of a suitable condensating agent, in an aprotic solvent at a temperature of between -70°C and 50°C.
20. (Currently Amended) The process according to Claim[s] 18 [or 19], in which said temperature is comprised between -10°C and 20°C.
21. (Original) A pharmaceutical composition comprising as active principle one or more compounds of formula (I) as described in Claim 1, or pharmaceutically acceptable salts or solvates thereof.
22. (Original) The pharmaceutical composition according to Claim 21, further comprising vectors, diluents and/or pharmaceutically acceptable excipients suitable for forms of administration chosen between oral, parenteral, rectal, transdermal, and transmucosal.
23. (Currently Amended) The pharmaceutical composition according to Claim[s] 21 [and 22], in the form of solutions, suspensions, soluble powders, granules, microcapsules, capsules, lozenges, tablets, coated tablets, suppositories, creams, ointments, lotions, pastes, medicated plasters, membranes or gels.
24. (Cancelled)
25. (Currently Amended) [The use according to claim 24,] Method according to claim 28, for the treatment of learning and memory deficits, Alzheimer's disease, dementia, senile dementia,

post stroke vascular type dementia, epilepsy, cerebral ischaemia, mood disorders, depression, for the treatment of conditions of chronic pain, inflammatory pain, neuropathic pain, visceral pain, and for the treatment of emesis.

26. (Currently Amended) [The use according to Claim 24,] Method according to claim 28, in which said compound of formula (I) is administered in association, concurrently or sequentially, with one or more other active principles.

27. (New) The process according to claim 19, in which said temperature is comprised between -20 and 10°C.

28. (New) Method for the treatment of diseases requiring nootropic and/or neuroprotective, analgesic and/or antihyperanalgesic, and anti-emetic action, characterized by administering, to a patient in need thereof, an effective amount of a compound of formula (I) as described in claim 1.